Previous Article | Next Article 
Journal of Virology, March 2000, p. 2414-2419, Vol. 74, No. 5
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Herpes Simplex Virus Type 1-Specific Cytotoxic
T-Lymphocyte Arming Occurs within Lymph Nodes Draining the Site of
Cutaneous Infection
Claerwen M.
Jones,1
Stephen C.
Cose,1
Richard M.
Coles,1
Adam C.
Winterhalter,2
Andrew G.
Brooks,3
William R.
Heath,4 and
Francis R.
Carbone1,*
Department of Pathology and Immunology,
Monash Medical School, Prahran, Victoria 3181,1
and Cooperative Research Centre for Vaccine Technology,
Department of Microbiology and Immunology, University of
Melbourne,2 Department of Microbiology
and Immunology, University of Melbourne,3 and
Immunology Division, The Walter and Eliza Hall Institute of
Medical Research,4 Parkville, Victoria 3050, Australia
Received 17 June 1999/Accepted 13 November 1999
 |
ABSTRACT |
Various studies have shown that major histocompatibility complex
class I-restricted cytotoxic T lymphocytes (CTL) can be isolated from
lymph nodes draining sites of cutaneous infection with herpes simplex
virus type 1 (HSV-1). Invariably, detection of this cytolytic activity
appeared to require some level of in vitro culture of the isolated
lymph node cells, usually for 3 days, in the absence of exogenous viral
antigen. This in vitro "resting" period was thought to represent
the phase during which committed CD8+ T cells become
"armed" killers after leaving the lymph nodes and prior to their
entry into infected tissue as effector CTL. In this study we reexamined
the issue of CTL appearance in the HSV-1 immune response and found that
cytolytic activity can be isolated directly from draining lymph nodes,
although at levels considerably below those found after in vitro
culture. By using T-cell receptor elements that represent effective
markers for class I-restricted T cells specific for an immunodominant
glycoprotein B (gB) determinant from HSV-1, we show that the increase
in cytotoxicity apparent after in vitro culture closely mirrors the
expansion of gB-specific CTL during the same period. Taken together,
our results suggest that HSV-1-specific CTL priming does not appear to
require any level of cytolytic machinery arming outside the lymph node
compartment despite the absence of any detectable infection within that site.
 |
INTRODUCTION |
Major histocompatibility complex
(MHC) class I-restricted cytotoxic T lymphocytes (CTL) can play a
critical role in antiviral immune responses (40). These T
cells facilitate viral clearance by directly lysing target cells
harboring productive virus infection. In the case of the human immune
response to herpes simplex virus type 1 (HSV-1), CD8+ T
cells can be isolated from infected individuals (32). In addition, the recent identification of the HSV-encoded ICP47 protein, which blocks class I-restricted peptide presentation, suggests that CTL
lysis plays an important role during the antiviral response (11,
15, 39). In mouse model systems, CD8+ T cells can be
isolated from lymph nodes draining the site of cutaneous primary
infection, and these T cells effectively protect animals against
subsequent infection (2, 3, 13, 22, 28). However, unlike
many primary antiviral responses, T cells isolated from lymph nodes
draining sites of cutaneous HSV-1 infection did not appear to kill
infected target cells without being subjected to a period of in vitro
culture, usually in the absence of exogenous antigen (6, 27,
30). This culture period was thought to reflect a need for
extralymphoid differentiation into armed cytotoxic effectors capable of
dealing with the peripheral infection. Such a proposal is consistent
with the notion that while CTL precursors are activated within the
draining lymph nodes, the cytotoxic effectors are required only within
the actual sites harboring infective virus, in this case the infected footpads.
We have examined the CD8+ CTL response to footpad infection
with HSV-1. This response is dominated by T cells specific for a single
Kb-restricted determinant derived from the glycoprotein B
(gB) (28, 34). We have shown that these CD8+ T
cells are restricted with respect to their T-cell receptor (TCR)
expression with approximately 60% bearing a V
10+
-chain containing a highly conserved junctional sequence
(9). This pattern of TCR expression permitted visualization
of HSV-specific T cells directly ex vivo and revealed that this
specificity dominated the activated CD8+ T-cell subset
(8). The results suggested that these T cells may be fully
activated within the lymph node environment and therefore would
potentially not require any period of peripheral arming. We show here
that cytotoxicity can indeed be isolated directly from the lymph nodes
draining sites of cutaneous infection and further show that the in
vitro culture period involves a rapid expansion of gB-specific CTL.
 |
MATERIALS AND METHODS |
Mice, virus, and cell lines.
C57BL/6 mice were purchased
from the Central Animal Facility at Monash University, Clayton,
Victoria, Australia. The KOS strain of HSV-1 was propagated, and the
titers were determined by using Vero cells. The gB peptide with the
sequence SSIEFARL (single letter amino acid code) corresponding to
residues 498 to 505 in HSV-1 gB was synthesized by using an Applied
Biosystems model 431A synthesizer (ABI, Foster City, Calif.) and kindly
provided by J. Fecondo, Swinburne University of Technology, Hawthorn,
Victoria, Australia. The H-2b thymoma cell line
EL4 was grown in Dulbecco's modified Eagle medium (DMEM) containing
10% fetal calf serum (FCS), 4 mM glutamine, 5 × 10
5 M 2-mercaptoethanol, and antibiotics (complete DMEM).
Injection with HSV-1.
Mice were injected in each hind
footpad with 4 × 105 PFU HSV-1 in phosphate-buffered
saline (PBS), and the draining popliteal lymph nodes were removed 5 days later. Viable cell counts were determined for all lymph node
samples by trypan blue exclusion prior to analysis. Lymph node cells
were analyzed directly ex vivo or after 3 days in culture in wells of a
96-well flat-bottom plate at a density of 106 cells/well in
250 µl RPMI containing 10% FCS, 2 mM glutamine, 5 × 10
5 M 2-mercaptoethanol, and antibiotics (complete RPMI)
without exogenous antigen.
Assessment of gB-specific CTL activity.
CTL lysis was
assessed by a 4-h chromium release assay with 51Cr (150 µCi)-labeled EL4 cells that had or had not been pulsed with 1 µg of
gB peptide per ml. Effector/target ratios ranged from 100:1 to 0.1:1 in
the assay. Results are expressed as a percentage of specific lysis with
spontaneous lysis less than 20% for target cells.
H-2Kb/gB tetramer.
Tetrameric
H-2Kb/gB peptide complexes were prepared
essentially as described by Altman and coworkers (1).
Briefly, recombinant H-2Kb and human
2-microglobulin, produced in Escherichia
coli, were dissolved in urea and injected together with the gB
peptide into a refolding buffer consisting of 100 mM Tris pH 8.0, 400 mM arginine, 2 mM EDTA, 5 mM reduced glutathione, and 0.5 mM oxidized
glutathione. Refolded complexes were purified by anion-exchange
chromatography by using DE52 resin (Whatman International, Ltd.,
Maidstone, England) followed by gel filtration through a Superdex 75 column (Amersham Pharmacia Biotech, Uppsala, Sweden). The refolded
H-2Kb/gB peptide complexes were biotinylated by incubation
for 16 h at 30°C with the BirA enzyme (Avidity, Boulder, Colo.).
Tetrameric MHC-peptide complexes were produced by the stepwise addition
of extravidin-conjugated phycoerythrin (Sigma, St. Louis, Mo.) to achieve a 1:4 molar ratio (extravidin-phycoerythrin-biotinylated H-2Kb/gB peptide complexes).
Flow cytometry.
Lymph node cells analysed directly ex vivo
or after 3 days in culture without exogenous antigen were triple
stained with allophycocyanin-labeled anti-CD8 (53-6.7; Pharmingen, San
Diego, Calif.), phycoerythrin-labeled anti-CD25 (PC61; Pharmingen), and
biotin-labeled anti-V
10 (B21.5; Pharmingen), followed by
streptavidin-fluorescein isothiocyanate (FITC) (Molecular Probes, Inc.,
Eugene, Oreg.). Dead cells were excluded by using propidium iodide, and
the cells were visualized on a Becton Dickinson FACScalibur. Live gates
were set on lymphocytes, using forward and side scatter profiles, and
100,000 live cells were collected for analysis.
Lymph node cells cultured for 3 days without exogenous antigen were
also stained with allophycocyanin-labeled anti-CD8 (53-6.7; Pharmingen)
and FITC-labeled anti-CD25 (PC61.5.3; Cedarlane Laboratories, Ltd.,
Hornby, Ontario, Canada). After 20 min of incubation on ice, the cells
were washed in PBS-bovine serum albumin (BSA)-azide (PBS, pH 7.45;
0.5% BSA; 0.02% sodium azide). The cells were then stained with
phycoerythrin-conjugated H-2Kb/gB tetramers and incubated
at 37°C for 15 min and on ice for 5 min before washing them in
PBS-BSA-azide. Dead cells were excluded by using propidium iodide, and
the cells were visualized with a Becton Dickinson FACScalibur
apparatus. Live gates were set on lymphocytes, using forward and side
scatter profiles, and 100,000 live cells were collected for analysis.
CFSE labeling.
Popliteal lymph nodes from three mice
injected in the hind footpads 5 days earlier with HSV-1 were removed,
the two lymph nodes for each mouse were pooled, and viable cell counts
were determined for each lymph node sample. Cells were resuspended in
PBS containing 0.1% BSA at a density of 107 cells/ml. For
fluorescence labeling, 2 µl of a
5,6-carboxy-succinimidyl-fluorescein-ester (CFSE; Molecular Probes,
Inc.) stock solution (5 mM in dimethyl sulfoxide) was incubated with
107 cells for 10 min at 37°C as previously described
(16, 21). Viable cell counts were again determined for each
sample, and the cells were cultured for 3 days in wells of a 96-well
flat-bottom plate at a density of 106 cells/well in 250 µl of complete RPMI without exogenous antigen. Cells were then
stained with allophycocyanin-labeled anti-CD8 (53-6.7; Pharmingen) and
either biotin-labeled anti-V
10 (B21.5, Pharmingen) or biotin-labeled
anti-V
3 (KJ25; Pharmingen), followed by phycoerythrin-streptavidin
(Southern Biotechnology Associates, Birmingham, Ala.). Dead cells were
excluded by using propidium iodide, and the cells were visualized with
a Becton Dickinson FACScalibur apparatus. Live gates were set on
lymphocytes, using forward and side scatter profiles, and 50,000 live
cells were collected for analysis.
PCR analysis.
The hind feet and draining popliteal lymph
nodes from HSV-1-footpad injected mice were removed 12, 24, and 72 h postinoculation and digested overnight at 55°C in 500 µl of a
solution consisting of 50 mM Tris-HCl (pH 8.0), 100 mM EDTA, 0.5%
sodium dodecyl sulfate and 0.52 mg of proteinase K per ml. Genomic DNA
was isolated by phenol-chloroform extraction, followed by precipitation
with ethanol. The pellets were washed with 70% ethanol and resuspended
in 100 µl of TE buffer (10 mM Tris-HCl, pH 8.0; 1 mM EDTA). HSV-1 DNA was amplified by PCR by using 25 ng of genomic DNA, 50 pmol of primers,
0.2 mM deoxynucleoside triphosphate and 1.5 U of Taq polymerase (Gibco BRL, Rockville, Md.). The primers used for PCR amplification were HSV-1a (5'-CCCTGTCTCGCGCGACGGAC-3') and
HSV-1b (5'-TCACCGACCCATACGCGTAA-3') (20).
Amplification involved a single cycle of 95°C for 5 min, 55°C for 1 min, and 72°C for 2 min, followed by 30 cycles of 93°C for 30 s, 55°C for 1 min, and 72°C for 1 min and one final cycle of 93°C
for 30 s, 55°C for 1 min, and 72°C for 7 min with a DNA
Thermal Cycler (Perkin-Elmer Cetus, Norwalk, Conn.). For each specimen,
25 ng of genomic DNA was evaluated for amplification competence by PCR
by using insulin primers (5'-CGAGCTCGAGCCTGCCTATCTTTCAGGTC-3'
and 5'-CGGGATCCTAGTTGCAGTAGTTCTCCAG-3'). A 20-µl
aliquot of each PCR product was analyzed by electrophoresis on a 2%
agarose gel stained with ethidium bromide.
The draining popliteal lymph nodes from HSV-1-injected mice were also
removed 5 days postinoculation (at the peak of the primary
CTL
response) and cultured for 3 days without exogenous antigen
before
overnight digestion with proteinase K and phenol-chloroform
extraction
of genomic DNA. The DNA was amplified by PCR with primers
for HSV-1 and
insulin as
before.
Determination of virus titer.
The hind feet of mice infected
with HSV-1 were removed at the ankle, and individual feet were ground
in a 5-ml homogenizer (Laboratory Supply) with 1.5 ml of complete RPMI
to make a 20% (wt/vol) suspension. The draining popliteal lymph nodes
were similarly ground in a homogenizer to produce a 2% (wt/vol)
suspension. These suspensions were frozen at
70°C and then thawed
rapidly and centrifuged at 12,000 × g for 10 min at
4°C. The supernatant fluid was used immediately in a PFU assay on
Vero cells to determine the virus titer. Briefly, serial 10-fold
dilutions of the supernatant fluids were made in serum-free minimal
essential medium (MEM) and added to confluent monolayers of Vero cells
in six-well multiwell dishes (0.9 ml of supernatant/well). After 1 h of incubation at room temperature with occasional rocking, 3 ml of
1% agarose in MEM-2 (MEM containing 2% FCS, 4 mM glutamine, 5 × 10
5 M 2-mercaptoethanol, and antibiotics) was added to
each well. The plates were incubated at 37°C for 4 days before being
fixed with 10% formalin in phosphate buffer (4 ml/well). After 1 h of incubation at room temperature, the formalin and agarose were removed, and the cell monolayers were stained with 0.01% crystal violet to visualize the plaques. Results are expressed as the log of
the number of PFU of virus per tissue (i.e., footpad or lymph node).
The minimum level of virus that could be reliably detected was
log10 0.48.
 |
RESULTS |
HSV-1 can be detected in footpads after immunization but not in the
draining popliteal lymph nodes.
Cutaneous infection with HSV-1 has
in the past been associated with an absence of cytotoxicity in lymph
nodes draining the site of infection (27, 30). This lack of
lytic activity has been attributed to an absence of virus replication
in this site since it has been assumed that cytotoxicity would only be
necessary in the presence of virus-infected cells (17). We
wanted to confirm the absence of virus within these draining lymph
nodes. Figure 1 shows a comparison of
virus isolation from footpads after infection with HSV-1 and from
popliteal lymph nodes draining the infected tissues. It is obvious that
replicating virus is found within the site of cutaneous infection but
not in the draining lymph nodes. Thus, it would seem that any lymph
node-derived cytotoxicity would not be required for actual clearance of
infectious virus from this site.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 1.
Virus isolation from footpads and draining lymph nodes
following HSV-1 infection. Mice were infected in the hind footpads with
4 × 105 PFU of HSV-1 and 1 to 8 days later the hind
feet and popliteal lymph nodes were removed and homogenized. The
resulting supernatant fluids were used in a PFU assay on Vero cells to
determine the virus titer. The results are expressed as the log of the
number of PFU of virus per tissue (i.e., footpad or lymph node). Each
bar represents the mean and standard deviation of the footpads or lymph
nodes from three mice. The minimum level of detection is
log10 0.48.
|
|
It remained possible that some lymph node cells could be infected with
virus but might not be capable of supporting a full
round of virus
replication (that is, the cells might undergo an
abortive virus
infection). To exclude this possibility, we attempted
to amplify virus
DNA from isolated lymph nodes cells by PCR using
oligonucleotides
specific for HSV-1 (
20). These experiments
were carried out
12, 24, and 72 h postinfection (Fig.
2). Specific
bands were clearly amplified
from the infected tissues in contrast
to draining lymph nodes where no
virus DNA was detected. Similarly,
no virus DNA was detected in
draining lymph node cells taken 5
days after HSV infection and cultured
for 3 days without exogenous
antigen (Fig.
2). Consequently, lymphoid
organs appear to contain
very few, if any, virus-infected cells.

View larger version (51K):
[in this window]
[in a new window]
|
FIG. 2.
Presence of virus DNA in footpads and draining lymph
nodes following HSV-1 infection. Mice were infected in the hind
footpads with 4 × 105 PFU of HSV-1, and 12, 24, and
72 h later the hind feet and popliteal lymph nodes were removed
and digested overnight with proteinase K. The genomic DNA was isolated
by phenol-chloroform extraction, and 25 ng of genomic DNA was amplified
by PCR with primers specific for HSV-1 or for insulin. Genomic DNA,
extracted from popliteal lymph node cells which had been isolated from
mice 5 days after HSV-1 infection and cultured for 3 days without
exogenous antigen, was also amplified by PCR with primers specific for
HSV-1 or for insulin (in vitro).
|
|
In vitro culture of popliteal lymph node cells results in an
increase in HSV-specific CTL activity.
Early studies had shown
that while CTL from lymph nodes draining sites of HSV-1 infection
failed to lyse infected targets directly ex vivo, these same cells
could be converted to good effectors by culturing them for 3 days in
vitro in the absence of exogenous antigen (30, 31). We had
previously shown that HSV-1 gB-specific CD8+ T cells could
be detected within the activated subset of popliteal lymph nodes
draining infected tissues with the V
10 marker in combination with
TCR
-chain sequences, which are both signatures for this specificity
(8). We reasoned that by using relatively high
effector/target ratios we might detect some cytotoxicity associated
with these gB-specific T cells without the need for in vitro culture.
Figure 3 shows this to be the case.
However, these effectors are still about 40-fold less efficient, on the basis of the effector/target ratio that gives half maximal lysis, than
those derived after 3 days in culture.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 3.
An increase in gB-specific CTL is evident after 3 days
of culture without exogenous antigen. Three mice were infected in the
hind footpads with 4 × 105 PFU of HSV-1, and 5 days
later the cells from the individual draining popliteal lymph nodes were
collected, viable cell counts were performed, and 1 × 106 to 2 × 106 cells were placed into
culture without exogenous antigen. The remainder of the cells were
analysed directly ex vivo in a 4-h chromium release assay with
51Cr-labeled EL4 cells that had or had not been pulsed with
1 µg of gB peptide per ml at the effector/target ratios indicated.
After 3 days the cultured cells were harvested, viable cell counts were
performed, and the in vitro cells were also analyzed in a 4-h chromium
release assay. Specific lysis of 51Cr-labeled EL4 cells
alone was <2% by both ex vivo and in vitro effector cells.
|
|
The increase in cytotoxicity evident after in vitro culture
correlates with a corresponding expansion of CD8+ T cells
expressing biased V
10+ TCR indicative of gB
specificity.
The increase in cytotoxicity after in vitro culture
could be linked to maturation to full effector function or "arming"
of the effector cells (23, 24). The alternative explanation
is that this increase reflects the in vitro expansion of the specific T
cells. We had previously shown that the gB-specific CD8+ T
cells preferentially express a V
10+ TCR with a highly
restricted pattern of CDR3 sequence conservation (9). This
V
10+ T-cell bias can be used to detect the presence of
gB-specific CD8+ T cells within freshly isolated lymph node
cells where they preferentially reside in the activated T-cell subset
(8). Figure 4 shows the preferential expression of V
10+ TCR in the
CD25+ CD8+ lymph node population, where CD25 is
used as a marker for activation. Approximately 45% of the activated
CD8+ cells isolated directly ex vivo are
V
10+. However, this represents only 0.4% of all lymph
node cells. In contrast, 14% of cells recovered after the 3-day in
vitro culture of these popliteal cells are V
10+
CD8+ CD25+, indicative of a 35-fold increase in
the proportion of cells specific for gB. Indeed, the CD25+
CD8+ cultured lymph node cells are clearly gB specific, as
determined by direct staining with a tetrameric class I reagent
consisting of H-2Kb and the gB peptide (Fig.
5). This 35-fold increase in the
proportion of gB-specific CD8+ T cells is comparable to the
40-fold increase in CTL activity evident after the in vitro culture
(Fig. 3).

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 4.
V 10 expression by CD8+ CD25+
activated T cells from the draining lymph nodes of HSV-1-infected mice
determined directly ex vivo or after 3 days of culture without
exogenous antigen. Three mice were infected in the hind footpads with
4 × 105 PFU of HSV-1, and 5 days later the cells from
the draining popliteal lymph nodes were collected, viable cell counts
were performed, and 1 × 106 to 2 × 106 cells were placed into culture without exogenous
antigen. Another 106 cells were triple stained with V 10,
CD25, and CD8 antibodies prior to analysis by flow cytometry. After 3 days the cultured cells were similarly analyzed by flow cytometry. Dead
cells were excluded by using propidium iodide staining. The dot plots
represent CD8 versus CD25 staining for the popliteal lymph node cells
ex vivo, and after 3 days in culture without exogenous antigen (in
vitro). The histogram shows the V 10 receptor expression of the
CD8+ CD25+ T cell subsets. The percentage of
CD8+ CD25+ cells in the lymph nodes, and the
percentage of V 10+ T cells among the CD8+
CD25+ T cell subsets are shown as a mean and standard
deviation for the three mice analyzed.
|
|

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 5.
The CD8+ CD25+ T cells from the
draining lymph nodes of HSV-1-infected mice analyzed after 3 days of
culture without exogenous antigen are predominantly gB specific. A
mouse was infected in the hind footpads with 4 × 105
PFU of HSV-1, and 5 days later the cells from the draining popliteal
lymph nodes were collected and placed into culture without exogenous
antigen. After 3 days, the cultured cells and lymph node cells isolated
from a naive mouse were triple stained with CD25 and CD8 antibodies,
and the H-2Kb/gB tetramer and analyzed by flow cytometry.
Dead cells were excluded by using propidium iodide staining. The dot
plot represents CD8 versus CD25 staining for the cultured popliteal
lymph node cells. The histograms show the level of H-2Kb/gB
tetramer staining of the CD8+ CD25hi and
CD8+ CD25lo T cell subsets from the cultured
(shaded) and naive (unshaded) lymph node cell populations.
|
|
The preceding results suggest that the bulk of the increase in
cytotoxicity appears to come from the in vitro proliferation
of the
specific cells rather than from their maturation to armed
effectors.
The fate of cells labeled with the fluorescent dye
CFSE clearly shows
that T cells bearing the gB-biased V

10 receptor
preferentially
proliferate in these cultures (Fig.
6).
CFSE labeling
allows visualization of cellular proliferation by
detecting dilution
of the fluorescent dye by flow cytometry, with each
cell cycle
resulting in a halving of the fluorescence intensity
(
16,
21).
In this experiment V

3
+ T cells were
used as a negative control since, unlike V

10, this
V-region is not
overrepresented within the final gB-specific CTL
population
(
9). Overall, V

3
+ T cells make up less than
5% of all CD8
+ T cells remaining after 3 days in culture
(data not shown). Figure
5 shows that 86% of V

10
+
CD8
+ T cells have undergone proliferation after 3 days in
culture,
compared with only 33% of control V

3
+
CD8
+ T cells. This result is consistent with the notion
that the increase
in V

10
+ T cells over the 3-day culture
period is due to preferential
expansion of the gB-specific CTL.

View larger version (10K):
[in this window]
[in a new window]
|
FIG. 6.
Proliferation of gB-specific CD8+ T cells
following 3 days of culture. Three mice were infected in the hind
footpads with 4 × 105 PFU of HSV-1, and 5 days later
the cells from the draining popliteal lymph nodes were collected and
labeled with the fluorescent dye CFSE prior to culture without
exogenous antigen for 3 days. The cells were then stained with CD8 and
V 10 or V 3 antibodies prior to analysis by flow cytometry. Dead
cells were excluded by using propidium iodide staining. The histograms
show the proliferation (CFSE fluorescence) of the CD8+
V 10+ (gB-specific population) or CD8+
V 3+ (control population) T cells. The percentage of
proliferating cells in each subset is shown as a mean and standard
deviation for the three mice analyzed.
|
|
 |
DISCUSSION |
Cutaneous inoculation with HSV-1 results in the initial
replication of virus in epithelial tissues, followed by infection of
neuronal cells and the subsequent movement of virus to the sensory
ganglia (36). We show here that while infectious virus does
not make its way into the lymph nodes draining the site of infection,
the HSV-specific CTL response appears to be nonetheless initiated in
these lymphoid areas. This initiation is apparent from the actual
development of cytolytic activity (Fig. 3) and previously, from the
accumulation of activated CD8+ T cells bearing gB-specific
TCR
-chain sequences with the draining lymph nodes (8).
Given the absence of infection in the draining lymph nodes, CTL priming
requires that antigen, but not virus, is transported to this site, most
likely by professional antigen-presenting cells (APCs) such as
dendritic cells (5, 14). Dendritic cell migration is thought
to occur as a consequence of various forms of tissue insult, such as
microbial infection (38). The initial activation of CTL
directed to antigens found in peripheral tissues can occur within
draining lymph nodes in the total absence of any lymphoid-based antigen
expression (19). This process of class I-restricted indirect
presentation of antigen is thought to play a central role in immune
surveillance of antigens whose expression is confined to parenchymal
tissues (5, 14). In the case under study here, the
peripheral antigen is virus protein arising from cutaneous HSV-1
infection. This is in contrast to certain other localized infections,
such as those involving influenza and Sendai viruses, where infected
APCs can be isolated from draining lymph nodes where they are
presumably directly involved in CTL priming (12, 37).
Given the demonstration that virus is not found within the lymph node
compartment, it would have seemed reasonable to suggest that while the
specific CTL are activated within this site, full maturation to
cytotoxic effectors might occur after the T cell have emerged and
commenced their migration to infected tissues. Clearly, this was the
sentiment emerging from the previous studies showing an absence of
cytotoxicity from lymph node cells isolated directly ex vivo which
increased to relatively high levels after a period of in vitro culture
(17, 27, 30). However, we have shown that cytotoxic effector
function can be detected within these draining lymph nodes, albeit only
at modest levels that were probably missed by previous investigators
using relatively low effector/target ratios combined with HSV-infected
target cells, which are probably less sensitive than the peptide-pulsed
targets used here. We took advantage of this CTL detection in
combination with the TCR V
10 marker, which is a signature of
gB-specific T cells (9), to quantify the gB-specific
CD8+ T-cell numbers. These calculations show that the level
of cytotoxicity within the lymph nodes appears to be equivalent on a
specific-cell basis to that found after the in vitro culture period.
We cannot exclude some level of extralymphoid effector cell maturation.
Recent studies by McNally and coworkers also showed that the appearance
of cytotoxicity corresponded to the increased numbers of
CD8+ CD25+ cells within the cultures (23,
24). However, this was attributed to a "conversion" or
acquisition of cytotoxic effector function by the CTL precursors. In
contrast, our results suggest that the in vitro-mediated increased
cytotoxicity is largely a direct result of activation, and probably
proliferation, of the gB-specific CTL. In other words, the gB-specific
CD8+ T cells found within the draining lymph nodes appear
to be fully mature cytotoxic effectors. This rapid CTL arming is in
line with results from Oehen and Brduscha-Riem (29) showing
that CD8+ T cells are fully cytotoxic even after just one
round of division. Moreover, the appearance of cytotoxic effector
function in that study preceded the downregulation of the lymph node
homing receptor, CD62L. Combined, these results suggest that effector
function appears very shortly after T-cell activation and probably
before egress from the lymph nodes. The fact that this occurs in the absence of virus infection within the lymph nodes suggests that the
arming may require other elements found in this location, such as a
cytokine milieu compatible with the maturation to the fully cytotoxic
form of the CD8+ T cell (10, 33, 35).
Finally, the apparent paucity of direct ex vivo cytotoxicity in the
HSV-1 response is in sharp contrast to other antiviral responses, such
as that to lymphocytic choriomeningitis virus (LCMV), where there is a
very strong level of CD8+ T cell-mediated killing (7,
25). However, LCMV involves a much more widespread, disseminating
viral infection that includes all lymphoid tissues compared to the much
more localized cutaneous HSV-1 infection examined here. Consequently,
while up to 70% of splenic CD8+ T cells are specific for
LCMV (4, 26), only about 0.4% of cells within the draining
lymph nodes are directed to the major HSV-1-derived target determinant
(see Fig. 4), although these cells dominate the activated lymph node
T-cell subset (8). Therefore, while the lack of
lymphoid-based virus infection might have little consequence on CTL
arming it could have considerable impact on the level of effector
expansion. This proliferation could well require secondary antigen
recognition by the armed effectors, which in this case would occur
within the infected tissues. The issue of tissue-based T-cell
proliferation has not been examined in detail although recent
experiments examining the fate of autoreactive T cells has suggested
that this can be an important mechanism for CTL expansion
(18).
Overall, our results reinforce the notion that cutaneous infection with
HSV-1 involves CTL priming within lymph nodes draining the site of
infection by antigen transfer to this site. This priming results in the
full activation of CTL effectors despite the lack of active lymph node
infection. While these cells ultimately leave this site to deal with
cells harboring replicating virus, their effector status appears to be
determined early in the activation process and does not require any
level of extralymphoid maturation.
 |
ACKNOWLEDGMENTS |
We thank J. Altman and D. Garboczi for the recombinant
H-2Kb and human
2-microglobulin plasmids.
This work was supported by funding from the Australian Research
Council, the Australian National Health and Medical Research Council,
and the CRC for Vaccine Technology.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Pathology and Immunology, Monash Medical School, Commercial Rd.,
Prahran, Victoria 3181, Australia. Phone: 61-3-9903-0744. Fax:
61-3-9903-0731. E-mail:
carbone{at}cobra.path.monash.edu.au.
 |
REFERENCES |
| 1.
|
Altman, J. D.,
P. A. H. Moss,
P. J. R. Goulder,
D. H. Barouch,
M. G. McHeyzer-Williams,
J. I. Bell,
A. J. McMichael, and M. M. Davis.
1996.
Phenotypic analysis of antigen-specific T lymphocytes.
Science
274:94-96[Abstract/Free Full Text].
|
| 2.
|
Bonneau, R. H., and S. R. Jennings.
1989.
Modulation of acute and latent herpes simplex virus infection in C57BL/6 mice by adoptive transfer of immune lymphocytes with cytolytic activity.
J. Virol.
63:1480-1484[Abstract/Free Full Text].
|
| 3.
|
Bonneau, R. H.,
L. A. Salvucci,
D. C. Johnson, and S. S. Tevethia.
1993.
Epitope specificity of H-2Kb-restricted, HSV-1-, and HSV-2-cross-reactive cytotoxic T lymphocyte clones.
Virology
195:62-70[CrossRef][Medline].
|
| 4.
|
Butz, E. A., and M. J. Bevan.
1998.
Massive expansion of antigen-specific CD8+ T cells during an acute virus infection.
Immunity
8:167-175[CrossRef][Medline].
|
| 5.
|
Carbone, F. R.,
C. Kurts,
S. R. M. Bennett,
J. F. A. P. Miller, and W. R. Heath.
1998.
Cross-presentation: a general mechanism for CTL immunity and tolerance.
Immunol. Today
19:368-373[CrossRef][Medline].
|
| 6.
|
Carter, V. C.,
P. A. Schaffer, and S. S. Tevethia.
1981.
The involvement of herpes simplex virus type 1 glycoproteins in cell-mediated immunity.
J. Immunol.
126:1655-1660[Abstract].
|
| 7.
|
Cole, G. A.,
N. Nathanson, and R. A. Prendergast.
1972.
Requirement for theta-bearing cells in lymphocytic choriomeningitis virus-induced central nervous system disease.
Nature
238:335-337[CrossRef][Medline].
|
| 8.
|
Cose, S. C.,
C. M. Jones,
M. E. Wallace,
W. R. Heath, and F. R. Carbone.
1997.
Antigen-specific CD8+ T cell subset distribution in lymph nodes draining the site of herpes simplex virus infection.
Eur. J. Immunol.
27:2310-2316[Medline].
|
| 9.
|
Cose, S. C.,
J. M. Kelly, and F. R. Carbone.
1995.
Characterization of a diverse primary herpes simplex virus type 1 gB-specific cytotoxic T-cell response showing a preferential V bias.
J. Virol.
69:5849-5852[Abstract].
|
| 10.
|
Erard, F.,
M. T. Wild,
J. A. Garcia Sanz, and G. Le Gros.
1993.
Switch of CD8 T cells to noncytolytic CD8 CD4 cells that make Th2 cytokine and help B cells.
Science
260:1802-1805[Abstract/Free Full Text].
|
| 11.
|
Fruh, K.,
K. Ahn,
H. Djaballah,
P. Sempe,
P. M. Vanendert,
R. Tampe,
P. A. Peterson, and Y. Yang.
1995.
A viral inhibitor of peptide transporters for antigen presentation.
Nature
375:415-418[CrossRef][Medline].
|
| 12.
|
Hamilton-Easton, A., and M. Eichelberger.
1995.
Virus-specific antigen presentation by different subsets of cells from lung and mediastinal lymph node tissues of influenza virus-infected mice.
J. Virol.
69:6359-6366[Abstract].
|
| 13.
|
Hanke, T.,
F. L. Graham,
K. L. Rosenthal, and D. C. Johnson.
1991.
Identification of an immunodominant cytotoxic T-lymphocyte recognition site in glycoprotein B of herpes simplex virus by using recombinant adenovirus vectors and synthetic peptides.
J. Virol.
65:1177-1186[Abstract/Free Full Text].
|
| 14.
|
Heath, W. R.,
C. Kurts,
J. F. Miller, and F. R. Carbone.
1998.
Cross-tolerance: a pathway for inducing tolerance to peripheral tissue antigens.
J. Exp. Med.
187:1549-1553[Free Full Text].
|
| 15.
|
Hill, A.,
P. Jugovic,
I. York,
G. Russ,
J. Bennink,
J. Yewdell,
H. Ploegh, and D. Johnson.
1995.
Herpes simplex virus turns off the TAP to evade host immunity.
Nature
375:411-415[CrossRef][Medline].
|
| 16.
|
Hodgkin, P. D.,
J. H. Lee, and A. B. Lyons.
1996.
B cell differentiation and isotype switching is related to division cycle number.
J. Exp. Med.
184:277-281[Abstract/Free Full Text].
|
| 17.
|
Hudson, S. J., and J. W. Streilein.
1994.
Functional cytotoxic T cells are associated with focal lesions in the brains of SJL mice with experimental herpes simplex encephalitis.
J. Immunol.
152:5540-5547[Abstract].
|
| 18.
|
Kurts, C.,
F. R. Carbone,
M. F. Krummel,
K. M. Koch,
J. F. A. P. Miller, and W. R. Heath.
1999.
Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells.
Nature
398:341-344[CrossRef][Medline].
|
| 19.
|
Kurts, C.,
W. R. Heath,
F. R. Carbone,
J. Allison,
J. F. Miller, and H. Kosaka.
1996.
Constitutive class I-restricted exogenous presentation of self antigens in vivo.
J. Exp. Med.
184:923-930[Abstract/Free Full Text].
|
| 20.
|
Lucotte, G.,
C. Bathelier,
V. Lespiaux,
C. Bali, and T. Champenois.
1995.
Detection and genotyping of herpes simplex virus types 1 and 2 by polymerase chain reaction.
Mol. Cell. Probes
9:287-290[CrossRef][Medline].
|
| 21.
|
Lyons, A. B., and C. R. Parish.
1994.
Determination of lymphocyte division by flow cytometry.
J. Immunol. Methods
171:131-137[CrossRef][Medline].
|
| 22.
|
McLaughlin-Taylor, E.,
D. E. Willey,
E. M. Cantin,
R. Eberle,
B. Moss, and H. Openshaw.
1988.
A recombinant vaccinia virus expressing herpes simplex virus type 1 glycoprotein B induces cytotoxic T lymphocytes in mice.
J. Gen. Virol.
69:1731-1734[Abstract/Free Full Text].
|
| 23.
|
McNally, J. M.,
H. A. Andersen,
R. Chervenak, and S. R. Jennings.
1999.
Phenotypic characteristics associated with the acquisition of HSV-specific CD8 T-lymphocyte-mediated cytolytic function in vitro.
Cell. Immunol.
194:103-111[CrossRef][Medline].
|
| 24.
|
McNally, J. M.,
D. Dempsey,
R. M. Wolcott,
R. Chervenak, and S. R. Jennings.
1999.
Phenotypic identification of antigen-dependent and antigen-independent CD8 CTL precursors in the draining lymph node during acute cutaneous herpes simplex virus type 1 infection.
J. Immunol.
163:675-681[Abstract/Free Full Text].
|
| 25.
|
Moskophidis, D.,
S. P. Cobbold,
H. Waldman, and F. Lehmann-Grubbe.
1987.
Mechanism of recovery from acute virus infection: treatment of lymphocytic choriomeningitis virus-infected mice with monoclonal antibodies reveals that Lyt-2+ T lymphocytes mediate clearance of virus and regulate the antiviral antibody response.
J. Virol.
61:1867-1874[Abstract/Free Full Text].
|
| 26.
|
Murali-Krishna, K.,
J. D. Altman,
M. Suresh,
D. J. Sourdive,
A. J. Zajac,
J. D. Miller,
J. Slansky, and R. Ahmed.
1998.
Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection.
Immunity
8:177-187[CrossRef][Medline].
|
| 27.
|
Nash, A. A.,
R. Quartey-Papafio, and P. Wildy.
1980.
Cell-mediated immunity in herpes simplex virus-infected mice: functional analysis of lymph node cells during periods of acute and latent infection, with reference to cytotoxic and memory cells.
J. Gen. Virol.
49:309-317[Abstract/Free Full Text].
|
| 28.
|
Nugent, C. T.,
R. M. Wolcott,
R. Chervenak, and S. R. Jennings.
1994.
Analysis of the cytolytic T-lymphocyte response to herpes simplex virus type 1 glycoprotein B during primary and secondary infection.
J. Virol.
68:7644-7648[Abstract/Free Full Text].
|
| 29.
|
Oehen, S., and K. Brduscha-Riem.
1998.
Differentiation of naive CTL to effector and memory CTL: correlation of effector function with phenotype and cell division.
J. Immunol.
161:5338-5346[Abstract/Free Full Text].
|
| 30.
|
Pfizenmaier, K.,
H. Jung,
A. Starzinski-Powitz,
M. Rollinghoff, and H. Wagner.
1977.
The role of T cells in anti-herpes simplex virus immunity. I. Induction of antigen-specific cytotoxic T lymphocytes.
J. Immunol.
119:939-944[Abstract/Free Full Text].
|
| 31.
|
Pfizenmaier, K.,
A. Starzinski-Powitz,
M. Rollinghoff,
D. Falks, and H. Wagner.
1977.
T-cell-mediated cytotoxicity against herpes simplex virus-infected target cells.
Nature
265:630-632[CrossRef][Medline].
|
| 32.
|
Posavad, C. M.,
D. M. Koelle, and L. Corey.
1998.
Tipping the scale of herpes simplex virus reactivation: the important responses are local.
Nat. Med.
4:381-382[CrossRef][Medline].
|
| 33.
|
Sad, S.,
R. Marcotte, and T. R. Mosmann.
1995.
Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines.
Immunity
2:271-279[CrossRef][Medline].
|
| 34.
|
Salvucci, L. A.,
R. H. Bonneau, and S. S. Tevethia.
1995.
Polymorphism within the herpes simplex virus (HSV) ribonucleotide reductase large subunit (ICP6) confers type specificity for recognition by HSV type 1-specific cytotoxic T lymphocytes.
J. Virol.
69:1122-1131[Abstract].
|
| 35.
|
Seder, R. A.,
J. L. Boulay,
F. Finkelman,
S. Barbier,
S. Z. Ben Sassom,
G. Le Gros, and W. E. Paul.
1992.
CD8+ T cells can be primed in vitro to produce IL-4.
J. Immunol.
148:1652-1656[Abstract].
|
| 36.
|
Simmons, A.,
D. Tscharke, and P. Speck.
1992.
The role of immune mechanisms in control of herpes simplex virus infection of the peripheral nervous system.
Curr. Top. Microbiol. Immunol.
179:31-56[Medline].
|
| 37.
|
Usherwood, E. J.,
T. L. Hogg, and D. L. Woodland.
1999.
Enumeration of antigen-presenting cells in mice infected with Sendai virus.
J. Immunol.
162:3350-3355[Abstract/Free Full Text].
|
| 38.
|
Winzler, C.,
P. Rovere,
M. Rescigno,
F. Granucci,
G. Penna,
L. Adorini,
V. S. Zimmermann,
J. Davoust, and P. Ricciardi-Castagnoli.
1997.
Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures.
J. Exp. Med.
185:317-328[Abstract/Free Full Text].
|
| 39.
|
York, I. A.,
C. Roop,
D. W. Andrews,
S. R. Riddell,
F. L. Graham, and D. C. Johnson.
1994.
A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes.
Cell
77:525-535[CrossRef][Medline].
|
| 40.
|
Zinkernagel, R. M.
1996.
Immunology taught by viruses.
Science
271:173-178[Abstract].
|
Journal of Virology, March 2000, p. 2414-2419, Vol. 74, No. 5
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Mintern, J. D., Bedoui, S., Davey, G. M., Moffat, J. M., Doherty, P. C., Turner, S. J.
(2009). Transience of MHC Class I-restricted antigen presentation after influenza A virus infection. Proc. Natl. Acad. Sci. USA
106: 6724-6729
[Abstract]
[Full Text]
-
Walker, E. B., Miller, W., Haley, D., Floyd, K., Curti, B., Urba, W. J.
(2009). Characterization of the Class I-Restricted gp100 Melanoma Peptide-stimulated Primary Immune Response in Tumor-Free Vaccine-draining Lymph Nodes and Peripheral Blood. Clin. Cancer Res.
15: 2541-2551
[Abstract]
[Full Text]
-
Sheridan, B. S., Cherpes, T. L., Urban, J., Kalinski, P., Hendricks, R. L.
(2009). Reevaluating the CD8 T-Cell Response to Herpes Simplex Virus Type 1: Involvement of CD8 T Cells Reactive to Subdominant Epitopes. J. Virol.
83: 2237-2245
[Abstract]
[Full Text]
-
Lay, M. D. H., Zhang, L., Ribeiro, R. M., Mueller, S. N., Belz, G. T., Davenport, M. P.
(2009). Kinetics of Major Histocompatibility Class I Antigen Presentation in Acute Infection. J. Immunol.
182: 902-911
[Abstract]
[Full Text]
-
Jenkins, M. R., Mintern, J., La Gruta, N. L., Kedzierska, K., Doherty, P. C., Turner, S. J.
(2008). Cell Cycle-Related Acquisition of Cytotoxic Mediators Defines the Progressive Differentiation to Effector Status for Virus-Specific CD8+ T Cells. J. Immunol.
181: 3818-3822
[Abstract]
[Full Text]
-
Fischer, S. F., Belz, G. T., Strasser, A.
(2008). BH3-only protein Puma contributes to death of antigen-specific T cells during shutdown of an immune response to acute viral infection. Proc. Natl. Acad. Sci. USA
105: 3035-3040
[Abstract]
[Full Text]
-
Reading, P. C., Whitney, P. G., Barr, D. P., Wojtasiak, M., Mintern, J. D., Waithman, J., Brooks, A. G.
(2007). IL-18, but not IL-12, Regulates NK Cell Activity following Intranasal Herpes Simplex Virus Type 1 Infection. J. Immunol.
179: 3214-3221
[Abstract]
[Full Text]
-
Jenkins, M. R., Kedzierska, K., Doherty, P. C., Turner, S. J.
(2007). Heterogeneity of Effector Phenotype for Acute Phase and Memory Influenza A Virus-Specific CTL. J. Immunol.
179: 64-70
[Abstract]
[Full Text]
-
Knickelbein, J. E., Divito, S., Hendricks, R. L.
(2007). Modulation of CD8+ CTL Effector Function by Fibroblasts Derived from the Immunoprivileged Cornea. IOVS
48: 2194-2202
[Abstract]
[Full Text]
-
Mueller, S. N., Jones, C. M., Stock, A. T., Suter, M., Heath, W. R., Carbone, F. R.
(2006). CD4+ T Cells Can Protect APC from CTL-Mediated Elimination.. J. Immunol.
176: 7379-7384
[Abstract]
[Full Text]
-
Lang, A., Nikolich-Zugich, J.
(2005). Development and Migration of Protective CD8+ T Cells into the Nervous System following Ocular Herpes Simplex Virus-1 Infection. J. Immunol.
174: 2919-2925
[Abstract]
[Full Text]
-
Wojtasiak, M., Jones, C. M., Sullivan, L. C., Winterhalter, A. C., Carbone, F. R., Brooks, A. G.
(2004). Persistent expression of CD94/NKG2 receptors by virus-specific CD8 T cells is initiated by TCR-mediated signals. Int Immunol
16: 1333-1341
[Abstract]
[Full Text]
-
Belz, G. T., Smith, C. M., Kleinert, L., Reading, P., Brooks, A., Shortman, K., Carbone, F. R., Heath, W. R.
(2004). Distinct migrating and nonmigrating dendritic cell populations are involved in MHC class I-restricted antigen presentation after lung infection with virus. Proc. Natl. Acad. Sci. USA
101: 8670-8675
[Abstract]
[Full Text]
-
Yang, T. C., Dayball, K., Wan, Y. H., Bramson, J.
(2003). Detailed Analysis of the CD8+ T-Cell Response following Adenovirus Vaccination. J. Virol.
77: 13407-13411
[Abstract]
[Full Text]
-
Pellegrini, M., Belz, G., Bouillet, P., Strasser, A.
(2003). Shutdown of an acute T cell immune response to viral infection is mediated by the proapoptotic Bcl-2 homology 3-only protein Bim. Proc. Natl. Acad. Sci. USA
100: 14175-14180
[Abstract]
[Full Text]
-
Langelier, Y., Bergeron, S., Chabaud, S., Lippens, J., Guilbault, C., Sasseville, A. M.-J., Denis, S., Mosser, D. D., Massie, B.
(2002). The R1 subunit of herpes simplex virus ribonucleotide reductase protects cells against apoptosis at, or upstream of, caspase-8 activation. J. Gen. Virol.
83: 2779-2789
[Abstract]
[Full Text]
-
Coles, R. M., Mueller, S. N., Heath, W. R., Carbone, F. R., Brooks, A. G.
(2002). Progression of Armed CTL from Draining Lymph Node to Spleen Shortly After Localized Infection with Herpes Simplex Virus 1. J. Immunol.
168: 834-838
[Abstract]
[Full Text]
-
Estcourt, M. J., Ramsay, A. J., Brooks, A., Thomson, S. A., Medveckzy, C. J., Ramshaw, I. A.
(2002). Prime-boost immunization generates a high frequency, high-avidity CD8+ cytotoxic T lymphocyte population. Int Immunol
14: 31-37
[Abstract]
[Full Text]